285 related articles for article (PubMed ID: 33058716)
21. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
[TBL] [Abstract][Full Text] [Related]
22. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.
Yadav BS; Sharma SC; Malhotra P; Prakash G
J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
24. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
[TBL] [Abstract][Full Text] [Related]
25. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
26. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW; Li H; Schöder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; Noy A; Hsi ED; Cook JR; Lechowicz MJ; Gascoyne RD; Leonard JP; Kahl BS; Cheson BD; Fisher RI; Friedberg JW
J Clin Oncol; 2016 Jun; 34(17):2020-7. PubMed ID: 27069074
[TBL] [Abstract][Full Text] [Related]
27. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
28. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
30. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
31. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ; Jung SH; Pitcher B; Kostakoglu L; Grecula JC; Hsi ED; Schöder H; Popplewell LL; Chang JE; Moskowitz CH; Wagner-Johnston N; Leonard JP; Friedberg JW; Kahl BS; Cheson BD; Bartlett NL
Blood; 2018 Sep; 132(10):1013-1021. PubMed ID: 30049811
[TBL] [Abstract][Full Text] [Related]
32. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
33. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.
Franklin J; Eichenauer DA; Becker I; Monsef I; Engert A
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD008814. PubMed ID: 28901021
[TBL] [Abstract][Full Text] [Related]
34. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
Eich HT; Staar S; Gossmann A; Hansemann K; Skripnitchenko R; Kocher M; Semrau R; Engert A; Josting A; Franklin J; Krug B; Diehl V; Müller RP;
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1121-7. PubMed ID: 15001253
[TBL] [Abstract][Full Text] [Related]
35. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
[TBL] [Abstract][Full Text] [Related]
36. Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Bröckelmann PJ; Sasse S; Engert A
Blood; 2018 Apr; 131(15):1666-1678. PubMed ID: 29500174
[TBL] [Abstract][Full Text] [Related]
37. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
38. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
Diehl V; Franklin J; Pfreundschuh M; Lathan B; Paulus U; Hasenclever D; Tesch H; Herrmann R; Dörken B; Müller-Hermelink HK; Dühmke E; Loeffler M;
N Engl J Med; 2003 Jun; 348(24):2386-95. PubMed ID: 12802024
[TBL] [Abstract][Full Text] [Related]
39. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
40. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
